[ Price : $8.95]
FDA approves Mercks Keytruda (pembrolizumab) in combination with chemotherapy, with or without bevacizumab, for patients with pers...[ Price : $8.95]
Federal Register notice: FDA makes available a draft guidance entitled Select Updates for Unique Device Identification: Policy Reg...[ Price : $8.95]
Federal Register notice: FDA makes available a draft guidance entitled Q13 Continuous Manufacturing of Drug Substances and Drug Pr...[ Price : $8.95]
FDA releases the FDA-483 with five inspection observations issued following an inspection at Revance Therapeutics.[ Price : $8.95]
FDA accepts for priority review an Otsuka Pharmaceutical and H. Lundbeck supplemental NDA for Rexulti (brexpiprazole) for treating...[ Price : $8.95]
FDA grants Varian a breakthrough device designation for its Embozene microspheres for genicular artery embolization in treating sy...[ Price : $8.95]
FDA posts a draft guidance entitled Continuous Manufacturing of Drug Substances and Drug Products Q13.[ Price : $8.95]
Federal Register notice: FDA announces a 10/26 Vaccines and Related Biological Products Advisory Committee meeting to review and d...